Autoimmune mechanisms and inflammation in obesity-associated type 2 diabetes, atherosclerosis, and non-alcoholic fatty liver disease

被引:0
|
作者
Yuanyuan Sun [1 ]
Xueting Shan [1 ]
Mingyang Li [1 ]
Yifan Niu [4 ]
Zhongxin Sun [5 ]
Xiang Ma [1 ]
Tao Wang [3 ]
Jufang Zhang [2 ]
Dong Niu [1 ]
机构
[1] Zhejiang A&F University,College of Animal Science and Technology & College of Veterinary Medicine, Key Laboratory of Applied Technology on Green
[2] Westlake University,Eco
[3] Nanjing Kgene Genetic Engineering Co.,Healthy Animal Husbandry of Zhejiang Province, Provincial Engineering Research Center for Animal Health Diagnostics & Advanced Technology, Zhejiang International Science and Technology Cooperation Base for Veterinary M
[4] Ltd,Department of Plastic and Aesthetic Surgery, Affiliated Hangzhou First People’s Hospital, School of Medicine
[5] Zhejiang University,College of Animal Sciences
[6] Reconstructive & Hand Microsurgery,Department of Plastic
[7] Ningbo NO.6 Hospital,undefined
关键词
Obesity; Chronic inflammation; Metabolic Diseases; Pathophysiology;
D O I
10.1007/s10142-025-01587-0
中图分类号
学科分类号
摘要
Obesity, characterized by the excessive accumulation of white adipose tissue, is a significant global health burden and a major risk factor for a range of diseases, including malignancies and metabolic disorders. Individuals with high visceral fat content are particularly susceptible to severe complications such as type 2 diabetes, cardiovascular diseases, and liver disorders. However, the pathogenesis of obesity-related metabolic diseases extends beyond simple adiposity. Chronic obesity triggers a prolonged inflammatory response, which leads to tissue fibrosis and sustained organ damage, contributing to multi-organ dysfunction. This review explores the autoimmune mechanisms and inflammatory pathways underlying obesity-induced type 2 diabetes, atherosclerosis, and non-alcoholic fatty liver disease, with an emphasis on their interrelated pathophysiology and the potential for therapeutic interventions.
引用
收藏
相关论文
共 50 条
  • [41] Abdominal obesity, chronic inflammation and the risk of non-alcoholic fatty liver disease
    Zhao, Dongna
    Cui, Haozhe
    Shao, Zhiqiang
    Cao, Liying
    ANNALS OF HEPATOLOGY, 2023, 28 (04)
  • [42] Non-alcoholic fatty liver disease (NAFLD) is associated with an increased risk of type 2 diabetes mellitus
    Loosen, Sven H.
    Luedde, Tom
    Roderburg, Christoph
    JOURNAL OF HEPATOLOGY, 2023, 78 : S630 - S631
  • [43] Mapping of the circulating metabolome reveals α-ketoglutarate as a predictor of morbid obesity-associated non-alcoholic fatty liver disease
    E Rodríguez-Gallego
    M Guirro
    M Riera-Borrull
    A Hernández-Aguilera
    R Mariné-Casadó
    S Fernández-Arroyo
    R Beltrán-Debón
    F Sabench
    M Hernández
    D del Castillo
    J A Menendez
    J Camps
    R Ras
    L Arola
    J Joven
    International Journal of Obesity, 2015, 39 : 279 - 287
  • [44] Mapping of the circulating metabolome reveals α-ketoglutarate as a predictor of morbid obesity-associated non-alcoholic fatty liver disease
    Rodriguez-Gallego, E.
    Guirro, M.
    Riera-Borrull, M.
    Hernandez-Aguilera, A.
    Marine-Casado, R.
    Fernandez-Arroyo, S.
    Beltran-Debon, R.
    Sabench, F.
    Hernandez, M.
    del Castillo, D.
    Menendez, J. A.
    Camps, J.
    Ras, R.
    Arola, L.
    Joven, J.
    INTERNATIONAL JOURNAL OF OBESITY, 2015, 39 (02) : 279 - 287
  • [45] Reduction of obesity-associated white adipose tissue inflammation by rosiglitazone is associated with reduced non-alcoholic fatty liver disease in LDLr-deficient mice
    Petra Mulder
    Martine C. Morrison
    Lars Verschuren
    Wen Liang
    J. Hajo van Bockel
    Teake Kooistra
    Peter Y. Wielinga
    Robert Kleemann
    Scientific Reports, 6
  • [46] Kaempferol efficacy in metabolic diseases: Molecular mechanisms of action in diabetes mellitus, obesity, non-alcoholic fatty liver disease, steatohepatitis, and atherosclerosis
    Yao, Yu-xin
    Yu, Yu-jie
    Dai, Shu
    Zhang, Chao-yang
    Xue, Xin-yan
    Zhou, Meng-ling
    Yao, Chen-hao
    Li, Yun-xia
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 175
  • [47] Reduction of obesity-associated white adipose tissue inflammation by rosiglitazone is associated with reduced non-alcoholic fatty liver disease in LDLr-deficient mice
    Mulder, Petra
    Morrison, Martine C.
    Verschuren, Lars
    Liang, Wen
    van Bockel, J. Hajo
    Kooistra, Teake
    Wielinga, Peter Y.
    Kleemann, Robert
    SCIENTIFIC REPORTS, 2016, 6
  • [48] Non-alcoholic fatty liver disease associated molecular mechanisms of hepatocarcinogenesis
    Li, Bei
    Lu, Jiong
    You, Zhen
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2021, 14 (04): : 1559 - 1568
  • [49] Non-alcoholic fatty liver disease and type 2 diabetes mellitus: The liver disease of our age?
    Firneisz, Gabor
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (27) : 9072 - 9089